Mena-Vazquez, NataliaRojas-Gimenez, MartaFuego-Varela, ClaraGarcia-Studer, AimaraPerez-Gomez, NairRomero-Barco, Carmen MariaGodoy-Navarrete, Francisco JavierManrique-Arija, SaraGandia-Marinez, MyriamCalvo-Gutierrez, JerusalemMorales-Garrido, PilarMouriño-Rodriguez, CoralCastro-Perez, PatriciaAñon-Oñate, IsabelEspildora, FranciscoAguilar-Hurtado, Maria CarmenHidalgo-Conde, AnaArnedo-Diez de-Los-Rios, RocioCabrera-Cesar, EvaRedondo-Rodriguez, RocioVelloso-Feijoo, Maria LuisaFernandez-Nebro, Antonio2023-05-032023-05-032022-06-22Mena-Vázquez N, Rojas-Gimenez M, Fuego-Varela C, García-Studer A, Perez-Gómez N, Romero-Barco CM, et al. Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease. Biomedicines. 2022 Jun 22;10(7):14802227-9059http://hdl.handle.net/10668/20838To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept between 2015 and 2021. Patients were evaluated using high-resolution computed tomography and pulmonary function tests at initiation, 12 months, and the end of follow-up. The effectiveness of abatacept was evaluated based on whether ILD improved, stabilized, progressed, or was fatal. We also evaluated factors such as infection, hospitalization, and inflammatory activity using the 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR). Cox regression analysis was performed to identify factors associated with progression of lung disease. The study population comprised 57 patients with RA-ILD treated with abatacept for a median (IQR) of 27.3 (12.2-42.8) months. Lung disease had progressed before starting abatacept in 45.6% of patients. At the end of follow-up, lung disease had improved or stabilized in 41 patients (71.9%) and worsened in 13 (22.8%); 3 patients (5.3%) died. No significant decreases were observed in forced vital capacity (FVC) or in the diffusing capacity of the lung for carbon monoxide (DLCO).The factors associated with progression of RA-ILD were baseline DAS28-ESR (OR [95% CI], 2.52 [1.03-3.12]; p = 0.041), FVC (OR [95% CI], 0.82 [0.70-0.96]; p = 0.019), and DLCO (OR [95% CI], 0.83 [0.72-0.96]; p = 0.018). Only 10.5% of patients experienced severe adverse effects. Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AbataceptBiologicsInterstitial lung diseaseRheumatoid arthritisAGS - Jerez, Costa Noroeste y Sierra de CádizAGS - Sur de SevillaCarbon monoxideFollow-up studiesBlood sedimentationArthritis, rheumatoidLung diseases, interstitialRespiratory function testsVital capacityRegression analysisResearch article35884786open accessAnálisis de regresiónArtritis reumatoideCapacidad vitalEnfermedades pulmonares intersticialesEstudios de seguimientoMonóxido de carbonoPruebas de función respiratoriaSedimentación sanguínea10.3390/biomedicines10071480PMC9313094https://www.mdpi.com/2227-9059/10/7/1480/pdf?version=1656906270https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313094/pdf